Insider Selling: BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC) COO Sells 1,363 Shares of Stock

BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Get Free Report) COO Xiaobin Wu sold 1,363 shares of the firm's stock in a transaction dated Monday, June 23rd. The stock was sold at an average price of $260.00, for a total transaction of $354,380.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Xiaobin Wu also recently made the following trade(s):

• On Tuesday, June 17th, Xiaobin Wu sold 630 shares of BeOne Medicines stock. The stock was sold at an average price of $250.87, for a total transaction of $158,048.10.
• On Monday, June 16th, Xiaobin Wu sold 1,543 shares of BeOne Medicines stock. The shares were sold at an average price of $265.52, for a total transaction of $409,697.36.
• On Friday, June 6th, Xiaobin Wu sold 1,934 shares of BeOne Medicines stock. The shares were sold at an average price of $253.15, for a total transaction of $489,592.10.
• On Tuesday, April 1st, Xiaobin Wu sold 51,921 shares of BeOne Medicines stock. The shares were sold at an average price of $281.40, for a total transaction of $14,610,569.40.

BeOne Medicines Stock Down 5.2%

BeOne Medicines stock traded down $13.29 during trading hours on Friday, hitting $241.20. The stock had a trading volume of 400,801 shares, compared to its average volume of 340,778. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.96 and a quick ratio of 1.71. The company has a market cap of $26.44 billion, a PE ratio of -64.84 and a beta of 0.30. BeOne Medicines Ltd. - Sponsored ADR has a 12-month low of $141.84 and a 12-month high of $287.88. The stock has a 50-day simple moving average of $247.90.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping analysts' consensus estimates of ($0.71) by $1.93. BeOne Medicines had a negative net margin of 9.40% and a negative return on equity of 7.55%. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.12 billion. On average, research analysts expect that BeOne Medicines Ltd. - Sponsored ADR will post -5.82 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ONC shares. Morgan Stanley lifted their price target on shares of BeOne Medicines from $313.00 to $330.00 and gave the company an "overweight" rating in a research report on Friday. Bank of America raised shares of BeOne Medicines from a "neutral" rating to a "buy" rating and lifted their price target for the company from $207.00 to $320.00 in a research report on Monday, March 3rd. Guggenheim lifted their price target on shares of BeOne Medicines from $348.00 to $350.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. Macquarie lifted their price target on shares of BeOne Medicines from $259.00 to $313.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Finally, Royal Bank Of Canada upgraded shares of BeOne Medicines from an "outperform" rating to a "moderate buy" rating and set a $311.00 price objective for the company in a research note on Friday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, BeOne Medicines presently has an average rating of "Buy" and an average target price of $320.67.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.